Skip to content

Assessment of Endometrial and Sub-endometrial Vascularity Before and After PRP Infusion in Frozen Embryo Transfer Cycles

3D Power Doppler Ultrasound Assessment of Endometrial and Sub-endometrial Vascularity Before and After PRP Infusion in Frozen-thawed Embryo Transfer Cycles: a Pilot Study.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04247204
Enrollment
30
Registered
2020-01-29
Start date
2020-02-08
Completion date
2020-10-05
Last updated
2020-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frozen Embryo Transfer

Brief summary

A good quality embryo and receptive endometrium are important aspects in achieving optimal outcomes in assisted reproductive treatment (ART). Endometrial thickness is an important marker of uterine receptivity. A thin endometrium defined by an endometrial thickness ≤7mm was reported as a poor factor associated with significantly lower implantation and pregnancy rates as well as a higher risk of miscarriage. Nowadays, platelet-rich plasma (PRP) intrauterine infusion is a promising approach for the treatment of refractory thin endometrium in patients undergoing frozen-thawed embryo transfer. This is based on its ability to stimulate proliferation and angiogenesis with a large number of growth factors and cytokines i.e. the endometrium becomes thicker, with higher vascularity. PRP is easily prepared from an autologous blood sample that eliminates the risk of immunological reactions and transmission infections at low cost. Endometrial blood flow is another important marker reflective of uterine receptivity. Although publications are increasing concerning the efficacy of PRP intrauterine infusion on endometrial expansion and proliferation in frozen-thawed embryo transfer cycles, yet its angiogenetic effects have not been evaluated so far in either thin endometrium or normal endometrium thickness. Our study aims to evaluate endometrial and sub-endometrial vasculature patterns before and after PRP infusion in frozen-thawed embryo transfer cycles with normal endometrium thickness.

Interventions

BIOLOGICALPlatelet-rich plasma intrauterine infusion

For all women, basic transvaginal sonography will be done in the 2nd day of frozen embryo transfer (FET) cycle and they will receive standard hormone replacement therapy (HRT) in the form of estradiol valerate tablets (white tablets of Cyclo-Progynova; Bayer Schering Pharma AG, Germany) at a dose of 4mg for 7 days then 6mg for 6 days. Endometrial assessment will be done on day 15 of FET cycle. Those with endometrial thickness between 8-14 mm will be evaluated for endometrial and sub-endometrial vasculature pattern by 3D power Doppler analysis. Then 1 ml of PRP (prepared from autologous blood) will be infused in the uterine cavity and vaginal progesterone 400 mg twice daily will be prescribed for 3 days. Subsequently, D3 embryos will be transferred. Endometrial, sub-endometrial and uterine arterial vascularity pattern will be re-evaluated on the day of ET. Both estradiol valerate tablets and vaginal progesterone will be continued up to 12th week of gestation in case of pregnancy.

Sponsors

Hatem AbuHashim
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

* Subfertile women undergoing frozen-thawed embryo transfer with at least previously failed one ICSI cycle. * Age between 20-35 years. * Women with endometrium thickness between 8-14 mm on D15 of the frozen embryo transfer cycle

Exclusion criteria

* Women with a thin endometrium (≤ 7 mm) on day 15 of the cycle. * Women with known hematological or immunological disorders * Women with uncontrolled endocrine or other medical conditions, such as hyperprolactinemia or thyroid diseases. * Women with uterine abnormalities e.g. Asherman syndrome, myomas, uterine septum, bicornuate uterus. * Women who refuse to participate in the study.

Design outcomes

Primary

MeasureTime frameDescription
Vascularization index of the endometrial regionDay 15 to 18 of the frozen embryo transfer cycleVascularization index of the endometrial region will be measured by a researcher using the built-in VOCAL (Virtual Organ Computer-Aided Analysis) software for 3D power Doppler analysis.

Secondary

MeasureTime frameDescription
Flow index of the endometrial regionDay 15 to 18 of the frozen embryo transfer cycleFlow index of the endometrial region will be measured by a researcher using the built-in VOCAL (Virtual Organ Computer-Aided Analysis) software for 3D power Doppler analysis
Vascularization flow index of the endometrial regionDay 15 to 18 of the frozen embryo transfer cycleVascularization flow index of the endometrial region will be measured by a researcher using the built-in VOCAL (Virtual Organ Computer-Aided Analysis) software for 3D power Doppler analysis
Vascularization index of the sub-endometrial regionDay 15 to 18 of the frozen embryo transfer cycleVascularization flow index of the sub-endometrial region will be measured by a researcher using the built-in VOCAL (Virtual Organ Computer-Aided Analysis) software for 3D power Doppler analysis
Flow index of the sub-endometrial regionDay 15 to 18 of the frozen embryo transfer cycleFlow index of the sub-endometrial region will be measured by a researcher using the built-in VOCAL (Virtual Organ Computer-Aided Analysis) software for 3D power Doppler analysis
Vascularization flow index of the sub-endometrial regionDay 15 to 18 of the frozen embryo transfer cycleVascularization flow index of the sub-endometrial region will be measured by a researcher using the built-in VOCAL (Virtual Organ Computer-Aided Analysis) software for 3D power Doppler analysis

Contacts

Primary ContactHatem Abu Hashim, MD. FRCOG.PhD
hatem_ah@hotmail.com+20502300002

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026